Good find Nanonano. @Ecclescake, where I work job desrciptions never come within a million miles of the actual role. Sounds like a mid level position doing the grunt work under the FD. Just what I'd expect during early stage scale up.
I can't think of any reason to buy more at the moment. Need to see some of those corners turned first. You're taking a lot of risk on with Chinese tech at the moment though llol. Hats off if it pays off but there are lots of potetially existential problems out there.
Doesn't mean there's not a lot of work going on. Just that these things take a lot of time with open ended tasks and so progress difficult to report. If / when it hits it will hopefully be transformational.
I think that's the case Qd22. Costs should come down considerably in the next few years. Hopefully sales and margins will pick up as well with a new focus on the end customer. Looks like Lemos is cutting back on research though which might be a double edged sword.
I don't know. IQE say it's not down to loss of market share but to slower than expected 5G roll out. That has been corroborated by other sources but to what extent it's not easy to tell. There are never any hard numbers. Just stories of slow progress in various markets.
VCSELs aren't making as much as planned because customers are getting more chips from fewer wafers and Android OEMs don't seem to be picking up on whatever Apple are banging on about regarding FaceID and depth perception.
That and the delay to a few millitary contracts appears to sum up the bad performance. I'm not too concerned about the exceptional items as they all look like they're moving company in the direction of long term cost reduction.
I wouldn't say that the CEO needs to work a miracle. Especially since new use cases are springing up for compound semis all the time.
Technically in line with the recent guidance but they read badly. Negatives on the outlook front are that it seems the timetables for 5G and wifi 6 adoption are less certain. That's down the world being in turmoil so nothing the company can do about it. Positive signs are Lemos is adopting a new focus on sales and the end customer. Overall for the next couple of years low single digit growth. Should feel the benefits of site consolidation on top of that though.
This order in itself is not going to provide a lot of revenue as it is to cover development only for a 4th product. Woldn't be surprised to see full year come in at £2.2M or £2.3M. I don't think moving the R&D staff to Runcorn is directly as a result of this new contract but because they expect across all 4 they will soon be using Runcorn in earnest. They will have run test batches at volume before but that's very diferent to constant running. The best boffins are no doubt needed on site to refine and tweak the production line until it starts humming. The implication of that to me at least is that going into financial year 2023 Nanoco could be producing and selling lots :-)